A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. To evaluate the effect of MK-5475 versus placebo on 6-minute walk distance (6MWD) at Week 24
